Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis

Huo, Xingfa; Shen, Guoshuang; Wang, Tianzhuo; Li, Jinming; Xie, Qiqi; Liu, Zhen; Wang, Miaozhou; Zhao, Fuhua; Ren, Dengfeng; Zhao, Jiuda

doi:10.3389/fonc.2023.1003565

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is not one recommended sequence for patients receiving both local treatments and systemic therapy [ 83 ]. Medical treatments for BC are mainly based on hormone receptor and HER2 status, while some novel target therapies are available depending on the tumor molecular profile [ 7 , 82 , 84 ]. Pharmacological approaches for patients harboring encephalic disease do not differ from patients who do not, except for HER2-positive BC, for which guidelines providing a specific treatment algorithm have been provided [ 85 ].…”

Section: Targeting Therapies For Breast Cancer Patients With Brain Me...mentioning

confidence: 99%

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management

Ivanova,

Porta,

Giugliano

et al. 2023

Genes

View full text Add to dashboard Cite

Breast cancer is the most frequently diagnosed malignancy worldwide and the leading cause of cancer-related death among women. Brain metastases are a primary contributor to mortality, as they often go undetected until late stages due to their dormant nature. Moreover, the clinical management of brain metastases is complicated by the relevant issue of blood-brain barrier penetration. The molecular pathways involved in the formation, progression, and colonization of primary breast tumors and subsequent brain metastases are diverse, posing significant hurdles due to the heterogeneous nature of breast cancer subtypes. Despite advancements in primary breast cancer treatments, the prognosis for patients with brain metastases remains poor. In this review, we aim to highlight the biological mechanisms of breast cancer brain metastases by evaluating multi-step genetic pathways and to discuss currently available and emerging treatment strategies to propose a prospective overview of the management of this complex disease.

show abstract

Section: Targeting Therapies For Breast Cancer Patients With Brain Me...mentioning

confidence: 99%

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management

Ivanova,

Porta,

Giugliano

et al. 2023

Genes

View full text Add to dashboard Cite

show abstract

Metastatic brain tumors: from development to cutting‐edge treatment

Tanzhu,

Chen,

Ning

et al. 2024

MedComm

View full text Add to dashboard Cite

Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting‐edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood–brain barrier to achieve high intracranial concentrations, including small‐molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.

show abstract